ArticleNeuropharmacology2018
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
Open access · greenAbstract read
In one paragraph
Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review.CNS drugs · 2022Pooled it
- Emerging non-DFrontiers in psychiatry · 2026Review
- Beyond dopamine blockade: mechanistic humility and the rise of muscarinic, TAAR1, and glutamatergic pathways in schizophrenia.Frontiers in psychiatry · 2026Article
- Targeting muscarinic receptors for treating schizophrenia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Article
- From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.The international journal of neuropsychopharmacology · 2025Review
- [Pharmacological reports : PR · 2025Article
- A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.Nature reviews. Drug discovery · 2024Review
- Comparative transcriptomic rhythms in the mouse and human prefrontal cortex.bioRxiv : the preprint server for biology · 2024Article
- Activation of MBritish journal of pharmacology · 2024Article
- Normative modelling of molecular-based functional circuits captures clinical heterogeneity transdiagnostically in psychiatric patients.Communications biology · 2024Article
- The potential of muscarinic MFrontiers in psychiatry · 2024Review
- Comparative transcriptomic rhythms in the mouse and human prefrontal cortex.Frontiers in neuroscience · 2024Article
- The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders.Biochemical Society transactions · 2023Review
- A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia.Frontiers in cellular neuroscience · 2023Review
- Optimized Administration of the MACS chemical neuroscience · 2022Article
- Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.Translational psychiatry · 2022Review
- Effects of acute and repeated administration of the selective MAddiction biology · 2022Article
- Discovery of the First Selective MACS pharmacology & translational science · 2021Article
- Targeting muscarinic receptors to treat schizophrenia.Behavioural brain research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Robert W GouldDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Michael D GrannanDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Barak W GunterDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Jacob BallDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
Michael BubserDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Thomas M BridgesDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Jurgen WessLaboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.
Michael W WoodAstraZeneca, Neuroscience, Innovative Medicines & Early Development, Waltham, MA 02451, USA.
Nicholas J BrandonAstraZeneca, Neuroscience, Innovative Medicines & Early Development, Waltham, MA 02451, USA.
Mark E DugganAstraZeneca, Neuroscience, Innovative Medicines & Early Development, Waltham, MA 02451, USA.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Kennedy Center, Nashville, TN 37232, USA.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Kennedy Center, Nashville, TN 37232, USA.
Carrie K JonesDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: carrie.jones@vanderbilt.edu.
Vanderbilt University · USAstraZeneca (United States) · USNational Institutes of Health · US
Funding
Vanderbilt NCDDDG for Discovery of Novel Treatments for SchizophreniaU01MH087965 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY, LINDSLEY, CRAIG · 2010 to 2014
$9.3MMuscarinic receptor activators as novel antipsychotic agentsR01MH073676 · NIMH · VANDERBILT UNIVERSITY · PI Jerri Michelle Rook · 2006 to 2026
$9.3MResearch Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MIRNICS, KAROLY · 2015 to 2019
$7.1MMuscarinic acetylcholine receptor subtypes: physiological rolesZIADK075020 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI WESS, JURGEN · 2009 to 2025
$6.1MM4 Positive Allosteric Modulators for the Treatment of SchizophreniaR01MH086601 · NIMH · VANDERBILT UNIVERSITY · PI JONES, CARRIE KIMBERLY · 2009 to 2013
$1.9MPostdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0MNICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH073676NIMH NIH HHS R01 MH086601NIMH NIH HHS T32 MH093366NIMH NIH HHS U01 MH087965
Abstract
Although selective activation of the M
Indexed as
Allosteric RegulationAnimalsAntipsychotic AgentsBrainCognition DisordersDiscrimination, PsychologicalDisease Models, AnimalDizocilpine MaleateDose-Response Relationship, DrugHyperkinesisMaleMemory DisordersMiceMice, Inbred C57BLMice, KnockoutPyridazines5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno(2,3-c)pyridazine-6-carboxamideAntipsychotic AgentsDizocilpine MaleatePyridazinesReceptor, Muscarinic M4ThiophenesAntipsychotic-like activityCognitive enhancementM(4) muscarinic acetylcholine receptorMK-801Positive allosteric modulatorVU0467154
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.